fda bpc-157 ineligible for compounding 503a 503b FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the list now, ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them 503A vs 503B Compounding Pharmacies:

How do you bill Medicare for B12 injections

Medical-clinic pricing reflects pharmacy-grade compounding, provider supervision, and the legal framework around prescribing

Live Vitals clinician-gated model is exactly the right structure for that, but it means availability of specific compounds can change

Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS

For an academic group or a private lab this means a typical 2-5 working-day delivery without the paperwork associated with a non-EU import

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial